17 General Introduction 15. Hutson TE, Al-Shukri S, Stus VP, et al. Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial. Clin Genitourin Canc 2017;15(1):7276. (In English). DOI: 10.1016/j.clgc.2016.05.008. 16. Konishi S, Hatakeyama S, Tanaka T, et al. Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis. Med Oncol 2019;36(1) (In English). DOI: ARTN 6 10.1007/s12032-018-1231-3. 17. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. New Engl J Med 2013;369(8):722-731. (In English). DOI: 10.1056/NEJMoa1303989. 18. Schmidinger M, Bamias A, Procopio G, et al. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). Oncologist 2019;24(4):491-497. DOI: 10.1634/theoncologist.2018-0787. 19. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New Engl J Med 2019;380(12):1116-1127. (In English). DOI: 10.1056/ NEJMoa1816714. 20. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New Engl J Med 2019;380(12):1103-1115. (In English). DOI: 10.1056/NEJMoa1816047. 21. Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev 2020;86 (In English). DOI: ARTN 102019 10.1016/j. ctrv.2020.102019. 22. de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2020. DOI: 10.1056/NEJMoa1911440. 23. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clinical Cancer Research 2019;25(13):3753-3758. (In English). DOI: 10.1158/1078-0432.Ccr-18-4070. 24. Scott LJ. Larotrectinib: First Global Approval. Drugs 2019;79(2):201-206. (In English). DOI: 10.1007/ s40265-018-1044-x. 25. Priestley P, Baber J, Lolkema MP, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature 2019;575(7781):210-+. (In English). DOI: 10.1038/s41586-019-1689-y. 26. Clancy SB, W. . Translation: DNA to mRNA to Protein. Nature Education 2008;1(01):101. 27. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318(5848):287-90. DOI: 10.1126/science.1142946. 28. Clark DJ, Dhanasekaran SM, Petralia F, et al. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell 2019;179(4):964-983 e31. DOI: 10.1016/j.cell.2019.10.007. 29. Cutillas PR. Role of phosphoproteomics in the development of personalized cancer therapies. Proteom Clin Appl 2015;9(3-4):383-395. (In English). DOI: 10.1002/prca.201400104. 1
RkJQdWJsaXNoZXIy MTk4NDMw